Cytek Biosciences Q2 Revenue Up 6%, Raises Full-Year Guidance Midpoint by $1M

summarizeSummary

Cytek Biosciences reported Q2 2026 revenue of $48.1 million (+6% YoY), improved gross margins, but a wider net loss of $12.2 million. Full-year revenue guidance was raised slightly to $207–$212 million.

check_boxKey Events · Earnings and Guidance · CTKB

• Q2 Revenue +6% to $48.1M

  Revenue rose 6% year-over-year to $48.1 million, driven by instrument growth in the U.S. and China and continued service expansion.

• Gross Margin Improves, Loss Widens

  GAAP gross margin improved to 59% from 52%, but net loss widened to $12.2 million from $5.6 million due to a 15% increase in operating expenses, including litigation and severance costs.

• Full-Year Guidance Raised Modestly

  Cytek raised its 2026 revenue guidance to $207–$212 million, a $1 million increase at the midpoint, reflecting confidence in new product launches.

• Strong Cash Position

  Cash, equivalents, and marketable securities totaled $262.0 million as of June 30, 2026, providing ample runway despite widening losses.

auto_awesomeAnalysis · CTKB · Industrial Applications And Services

Cytek Biosciences delivered a mixed quarter: revenue grew 6% to $48.1 million, driven by instrument strength in the U.S. and China, and recurring revenue reached 35% of trailing-12-month sales. Gross margins improved sharply — GAAP 59% vs 52% a year ago — but operating expenses jumped 15%, pushing the net loss to $12.2 million from $5.6 million. The company raised its full-year revenue outlook to $207–$212 million, a modest $1 million midpoint increase, signaling confidence in new product launches like the Cytek Borealis. With $262 million in cash, the balance sheet remains solid, but widening losses and a recent senior sales executive departure add caution.